In 1968, Dr. Desh Bandhu Gupta founded Lupin with a conviction that India’s deadliest infectious disease could also be its greatest pharmaceutical opportunity. Tuberculosis killed hundreds of thousands each year. The drugs existed, but most Indians could not afford them. Five decades later, the company named after a nitrogen-fixing flower is the third-largest generic pharmaceutical company in the United States by prescriptions (per IQVIA).
The name Lupin comes from the Lupinus flower — a plant that fixes nitrogen in depleted soil, enriching the ground around it. Dr. Gupta chose it deliberately. His company would do for Indian public health what the flower does for farmland: make something essential grow where it could not grow before.
For its first two decades, Lupin was synonymous with anti-TB medicines. The company became one of the world’s largest manufacturers of rifampicin, the backbone of tuberculosis combination therapy. It was not glamorous work. It required process chemistry, cost discipline, and the patience to serve a market where the customers were often governments buying in bulk for national health programmes. But it built something that would matter enormously later: deep manufacturing capability and an institutional comfort with complex active pharmaceutical ingredients.
By the early 1990s, Lupin had a choice. It could remain an API supplier — profitable but dependent on a single therapeutic category — or it could use its chemistry expertise to enter finished-dosage generics in regulated markets. The company chose the harder path.
Lupin entered the United States in the early 2000s with generic cephalosporin antibiotics — a category where its API manufacturing strength gave it a cost advantage that was difficult to replicate. The company filed its own Abbreviated New Drug Applications, built its own regulatory team, and committed to owning the entire supply chain from molecule to pharmacy shelf.
The results were striking. By FY 2016, Lupin was the fifth-largest generic company in the US by prescriptions, with 43% of its global revenue coming from the American market. By FY 2017, it was fourth. By FY 2019, third — a position it still holds, with 174 products on the US market, 63 of them ranked number one in their category.
But the American market also taught Lupin its hardest lesson. Starting in FY 2018, generic drug prices in the United States began a sustained decline as buyers consolidated and competition intensified. Revenue dipped from $2.3 billion in FY 2019 to $1.8 billion in FY 2020. The company that had built its growth story on US generics had to find a way to grow beyond commodity pricing.
The difference between a simple generic and a complex one is the difference between following a recipe and reverse-engineering a meal. Complex generics — inhalation products, transdermal systems, long-acting injectables, biosimilars — require sophisticated formulation science, specialised manufacturing equipment, and years of clinical development. They also carry higher barriers to entry and more sustainable margins.
Lupin bet heavily on this transition. R&D investment reached INR 17.7 billion in FY 2025, funding a pipeline that spans respiratory devices, complex injectables, and biosimilars. The company holds 308 US FDA drug approvals (296 ANDAs, 11 NDAs, 1 BLA) and 195 Indian Patent Office grants — reflecting process and formulation innovations that protect genuinely novel delivery systems.
The strategy is visible in the numbers. Revenue recovered from the FY 2020 trough to reach $2.7 billion in FY 2025 — a record — driven not by volume growth in commodity generics but by a deliberate shift toward higher-value products. In India, Lupin ranks eighth in the domestic pharmaceutical market, with strengths in cardiovascular, respiratory, and diabetes therapies. Globally, it is the twelfth-largest generics company by sales.
Lupin operates in more than 100 countries, with manufacturing facilities in India, the United States, Brazil, and Mexico. In the US, it holds 453 ANDA and NDA filings with the FDA and ranks third among all generic companies by prescriptions filled. In India, it is the eighth-largest pharmaceutical company and a leader in cardiovascular, anti-diabetic, and respiratory therapies. In Japan, through its subsidiary Kyowa Pharmaceutical, it ranks among the largest generic manufacturers. In Latin America and Europe, it has built a growing presence through targeted acquisitions and organic launches.
Lupin operates fifteen manufacturing facilities across India, the United States, Brazil, and Mexico. Of these, fourteen carry US FDA registration — a density of regulatory compliance that reflects the company’s origins as an API manufacturer, where quality control is not an add-on but the core competence. The company controls the supply chain from active ingredient synthesis through finished dosage form, a vertical integration that traces directly back to the anti-TB manufacturing discipline of its early decades.
With 308 US FDA drug approvals (296 ANDAs, 11 NDAs, 1 BLA) and 195 Indian Patent Office grants, Lupin’s regulatory and intellectual property infrastructure operates at a scale that took five decades to build and cannot be quickly replicated.
Sources: Lupin Annual Reports FY2015–16 through FY2024–25. US FDA facility registration data. Indian patent office records.